Rexahn Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch REXN and buy or sell other stocks, ETFs, and their options commission-free!About REXN
Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders.
CEOGeorge Magrath, III, MD
CEOGeorge Magrath, III, MD
Employees18
Employees18
HeadquartersDurham, North Carolina
HeadquartersDurham, North Carolina
Founded2018
Founded2018
Employees18
Employees18
REXN Key Statistics
Market cap166.52M
Market cap166.52M
Price-Earnings ratio-1.17
Price-Earnings ratio-1.17
Dividend yield—
Dividend yield—
Average volume282.04K
Average volume282.04K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$2.59
52 Week high$2.59
52 Week low$0.65
52 Week low$0.65
Stock Snapshot
With a market cap of 166.52M, Rexahn Pharmaceuticals(REXN) trades at $2.58. The stock has a price-to-earnings ratio of -1.17.
On 2026-01-02, Rexahn Pharmaceuticals(REXN) shares started trading at —, with intraday highs of — and lows of —.
Trading activity shows a volume of 0, compared to an average daily volume of 282.04K.
Over the past 52 weeks, Rexahn Pharmaceuticals(REXN) stock has traded between a high of $2.59 and a low of $0.65.
Over the past 52 weeks, Rexahn Pharmaceuticals(REXN) stock has traded between a high of $2.59 and a low of $0.65.
People also own
Based on the portfolios of people who own REXN. This list is generated using Robinhood data, and it’s not a recommendation.